NasdaqGS:TNYABiotechs
Tenaya Therapeutics (TNYA) Valuation After TN-301 Data And New Alnylam Collaboration
Tenaya Therapeutics (TNYA) is back in focus after reporting a full year 2025 net loss of US$90.6 million, alongside fresh preclinical data and a new collaboration in cardiovascular and muscular disease programs.
See our latest analysis for Tenaya Therapeutics.
The recent MDA 2026 data for TN-301 and the new Alnylam collaboration appear to have sharpened market focus, with a 7 day share price return of 47.70% standing in contrast to a 36.86% decline over 90 days and a 3 year total shareholder...